Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia

This paper reports on a novel series of tyrosine kinase inhibitors (TKIs) potentially useful for the treatment of chronic myeloid leukemia (CML). The newly designed and synthesized compounds are structurally related to nilotinib (NIL), a second-generation oral TKI, and to a series of imatinib (IM)-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciaffaglione, Valeria, Consoli, Valeria, Intagliata, Sebastiano, Marrazzo, Agostino, Romeo, Giuseppe, Pittalà, Valeria, Greish, Khaled, Vanella, Luca, Floresta, Giuseppe, Rescifina, Antonio, Salerno, Loredana, Sorrenti, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143943/
https://www.ncbi.nlm.nih.gov/pubmed/35630697
http://dx.doi.org/10.3390/molecules27103220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143943/
https://www.ncbi.nlm.nih.gov/pubmed/35630697
http://dx.doi.org/10.3390/molecules27103220

Ejemplares similares